Business Wire

Lake House Group Chairman Donates 2.5 Million Masks to European Governments

29.4.2020 07:14:00 EEST | Business Wire | Press release

Share

In response to the impact of COVID-19 on European communities, Lake House Group Chairman Charles Brown has donated and coordinated delivery of 2.5 million masks to three European nations in order to stem the spread of the virus. He said “Masks are a low-cost, effective intervention for stopping the spread of the virus and getting people back to work safely.”

A Hong Kong native with European roots, Brown has donated one million masks each to the Kingdom of Spain and the Federal Republic of Germany, with an additional 500,000 masks designated for Région Sud in France. “The masks landed in Spain and Germany on 15 and 19 April, respectively, and the masks bound for southern France are currently in transit,” reported Torsten Hartmann, Managing Director for Europe in Lake House’s London office.

While traveling in Europe prior to widespread lockdowns, Brown noted with concern that few European citizens wore masks in public. Regarding Hong Kong’s low number of confirmed cases since the outbreak began there on 23 January, Brown stated “The 2003 SARS epidemic taught Hong Kongers to be vigilant about wearing masks, and that experience shows.”

The donation efforts have been spearheaded by Brian Lu, Venture Partner at the Japanese venture capital firm Infinity Ventures, in which Charles Brown is a Limited Partner. The firm’s portfolio company, Hong Kong-based logistics startup Buyandship, has worked to ensure the masks are delivered with as little burden as possible on the governments receiving the donations.

According to Lu, “We’ve seen how tough it’s been for governments to obtain masks from trusted sources and get them delivered efficiently, so we’re proud to be able to help these countries get masks into people’s hands as quickly as possible.”

“Giving money is an easy thing if you have it, but a more effective thing is to deliver the goods to the point where they are needed, and that’s what we’re trying to achieve here,” added Lake House’s Charles Brown. “I hope our efforts are able to spark other private donors to use their resources and connections to make similar efforts,” he said.

About Lake House Group

Established in 1995, Lake House Group is a private investment company founded by Hong Kong native Charles Brown, who is also Chairman Emeritus and Founding Board Member of the United Nations Peace Development Foundation in China. Lake House is led by CEO David Timblick, and invests in businesses across the globe at every stage. With offices in Hong Kong and London, the firm is involved in projects and investments in excess of US$15 billion across 15 countries.

About Infinity Ventures

Infinity Ventures is a venture capital firm, focused on early stage Internet companies, founded in Japan in 2008, with offices in Tokyo, Taipei, and Beijing. The firm manages $255M USD, and has invested in 91 startups and produced 9 IPOs. Since its founding, Infinity Ventures has grown alongside its portfolio companies to build category-leading innovators and unicorns including Groupon, Farfetch, freee, Yeahka, WealthNavi, and 17 Media.

About Buyandship

Buyandship is a cross-border e-commerce logistics company established in 2014. The company provides a one-stop transit service for goods bought in the United States, United Kingdom, Japan, Korea, and China. Buyandship currently maintains warehouses in multiple countries, with daily scheduled flights to Hong Kong and other markets in Asia.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Holly Harrington, Infinity Ventures
holly@infinityventures.com
+886936845447

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release

Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co

Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release

Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border

Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release

For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro

Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release

Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d

Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release

Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye